The in depth analysis on electrophysiology devices market outlook by OG analysis records a highest CAGR of 12.46% during the forecast period owing to degeneration of health and prevailing medical issues such as heart attacks, aging and high blood pressure which reflects cardio problems and scarring of the heart.
The segmented analysis on electrophysiology devices market size is based on key products (ablation catheters, laboratory devices, diagnostic catheters, access devices, and others), indications (atrial fibrillation, atrial flutter, atrioventricular nodal re-entry tachycardia (AVNRT), wolff-parkinson-white syndrome (WPW), and others), application (treatment devices, and monitoring devices), and by region wise across
South America & Central America
Middle East & Africa
Ablation catheters is rapidly emerging as the leading segment of the electrophysiology devices market during estimated period
Catheter ablation is widely adopted procedure to restore cardio regular rhythm and to control other heart rhythm problems such as atrial flutter and atrial fibrillation and is largely driven by the benefit of minimally invasive and removal of abnormal tissue without damaging the heart.
On May, 2019, Johnson & Johnson Medical Devices Companies announced the launch of Biosense Webster Inc.’s Cartonet to help electrophysiologists with the goal of improving patient outcomes and operational efficiency in catheter ablation procedures.
Increasing CVDs cases are evidently boosting the electrophysiology devices market demand
Cardiovascular disease is the leading global cause of death and is expected to rise to over 23.6 million by 2030. Amid CVDs, strokes and heart attacks are responsible for growing mortality rate.
CVD claims more lives and accounts for nearly 801,000 deaths in the US, followed by India driven by risk factors of metabolic, genetic, environmental and social environments.
New technological improvements in atrial fibrillation ablation systems and electro mapping are significantly driving the demand for electrophysiology devices market owing to benefits of reduction in repeated cardiac procedures and improved patient outcomes.
In early 2109, Biosense Webster, Inc. announced acquisition of Coherex Medical, Inc. along with launch of Coherex WaveCrest® - left atrial appendage occlusion system expand range of treatment options for patients with atrial fibrillation.
Prominent players contributing towards electrophysiology devices market growth